DISTINGUISHED INVESTIGATOR OF THERANOSTICS Trademark

Trademark Overview

On Tuesday, November 5, 2024, a trademark application was filed for DISTINGUISHED INVESTIGATOR OF THERANOSTICS with the United States Patent and Trademark Office. The USPTO has given the DISTINGUISHED INVESTIGATOR OF THERANOSTICS trademark a serial number of 98838242. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, January 27, 2026. This trademark is owned by Xcancer Software, LLC. The DISTINGUISHED INVESTIGATOR OF THERANOSTICS trademark is filed in the category with the following description:

Medical research, namely, conducting clinical trials in the field of cancer treatment.
distinguished investigator of theranostics

General Information

Serial Number98838242
Word MarkDISTINGUISHED INVESTIGATOR OF THERANOSTICS
Filing DateTuesday, November 5, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, January 27, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Certification Mark StatementThe certification mark, as used by persons authorized by the certifier, certifies that the provider of services has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.
Goods and ServicesMedical research, namely, conducting clinical trials in the field of cancer treatment.

Classification Information

International ClassB -
US Class CodesB
Class Status Code6 - Active
Class Status DateTuesday, November 5, 2024
Primary CodeB
First Use Anywhere DateTuesday, April 30, 2024
First Use In Commerce DateTuesday, April 30, 2024

Trademark Owner History

Party NameXcancer Software, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressOmaha, NE 68130

Trademark Events

Event DateEvent Description
Tuesday, November 5, 2024NEW APPLICATION ENTERED
Tuesday, June 10, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 11, 2025ASSIGNED TO EXAMINER
Wednesday, June 18, 2025NON-FINAL ACTION WRITTEN
Wednesday, June 18, 2025NON-FINAL ACTION E-MAILED
Wednesday, June 18, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 25, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 2, 2025ASSIGNED TO LIE
Tuesday, September 2, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 2, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 2, 2025NON-FINAL ACTION WRITTEN
Tuesday, December 2, 2025NON-FINAL ACTION E-MAILED
Tuesday, December 2, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 27, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 27, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 27, 2026TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

theranostics investigator distinguished field cancer treatment trials clinical research namely conducting medical